|
|
|
09.10.26 - 15:03
|
COLLPLANT ANNOUNCES A $3.7 MILLION PRIVATE PLACEMENT (PR Newswire)
|
|
|
Transaction Led Primarily by Existing Investors to Accelerate LightSolver's Laser-Based Supercomputing Development REHOVOT, Israel, Oct. 9, 2026 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), an innovative technology company operating at the intersection of deep-tech photonic......
|
|
|
|
|
08.10.26 - 14:01
|
Entera Bio Announces Additional Presentation of EB613 Phase 3 Study Design at the ASBMR 2026 Annual Meeting (GlobeNewswire EN)
|
|
|
TEL AVIV, Israel, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that an additional presentation highlighting the clinical study design for its planned Phase 3 registrational trial of EB613 (oral PTH(1-34) tablet) will be presented at the American Society for Bone and Mineral Research (ASBMR) 2026 Annual Meeting, taking place October 9-12, 2026, at the John B. Hynes Veterans Memorial Convention Center in Boston, Massachusetts....
|
|
|
|
|
|
|
05.10.26 - 09:54
|
Israel: Psychische Gesundheit in der Krise (DW)
|
|
|
Mehr als ein Drittel aller Israelis zeigt Symptome psychischer Erkrankungen. Drei Jahre nach den Angriffen vom 7. Oktober ist das Gesundheitssystem noch immer mit den Folgen des Terrorangriffs überfordert....
|
|
|
02.10.26 - 22:21
|
NeuroSense Provides Update on Nasdaq Listing Compliance (PR Newswire)
|
|
|
Company regains compliance with Nasdaq's minimum bid price requirement and intends to request a Nasdaq Hearings Panel hearing to seek additional time to regain compliance with the minimum market value requirement CAMBRIDGE, Mass., Oct. 2, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.......
|
|
|
|
|
01.10.26 - 15:01
|
PolyPid Regains European Commercialization Rights for D-PLEX₁₀₀, Expanding Global Commercialization Opportunities (GlobeNewswire EN)
|
|
|
PETACH TIKVA, Israel, Oct. 01, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that PolyPid and ADVANZ PHARMA have mutually agreed to terminate their 2022 exclusive License, Distribution and Supply Agreement for D-PLEX₁₀₀ in Europe. As a result, the exclusive European commercialization rights for D-PLEX₁₀₀ have reverted to PolyPid....
|
|
|
|
|
|
|
30.09.26 - 15:15
|
Sol-Gel Technologies to Host KOL Investor Day for SGT-610 on October 14, 2026 (GlobeNewswire EN)
|
|
|
NESS ZIONA, Israel, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with rare and severe skin conditions, today announced it will host a KOL Investor Event on SGT-610 (patidegib gel, 2%) on Wednesday, October 14, 2026 in New York....
|
|
|
|
|
29.09.26 - 14:31
|
Humanoid Global Highlights MBody AI′s Completion of Nasdaq Transaction and Commercial Robotics Deployment at Mohegan Sun (GlobeNewswire EN)
|
|
|
Vancouver, BC, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Humanoid Global Holdings Corp. (“Humanoid Global” or the “Company”) (CSE:ROBO, FWB:0XM1, OTCQB:RBOHF), a publicly traded investment issuer focused on building and accelerating a portfolio of pioneering companies in humanoid robotics and embodied artificial intelligence (“AI”), is pleased to highlight recent corporate and commercial developments announced by MBody AI Ltd. (“MBody AI”) (Nasdaq: MBAI), a portfolio company in which Humanoid Global holds a minority equity interest.MBody AI announced that, on August 26, 2026, Check-Cap Ltd. completed its business combination with MBody AI Corp. Under the transaction, MBody AI Corp. became a wholly owned subsidiary of Check-Cap, and Check-Cap shareholders approved a corporate name change to MBody AI Ltd. The combined company continues to trade on Nasdaq under the symbol MBAI.MBody AI further announced the closing, on August 27, 2026, of an underwritten public offering of 1,538,462 ordinary share...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
